Preparation Haymovis® represents hydrogel, which is produced in accordance with the requirements of Good Manufacturing Practice (Good Manufacturing Practice, GMP) and contains HYADD®4, a new molecule, patented by Fidia, at a concentration of 8 mg / ml. HYADD®4 is a new derivative of hyaluronic acid: Hyaluronic acid partial geksadetsilamid (partial due to the very low level of modification of hyaluronic acid, about 3% molar concentration to preserve the biological compatibility).
This structure gives the drug Haymovis® special properties, including a long delay time, as well as visco-elastic properties in addition to the excellent lubricating properties of the drug.
elastic recovery. In contrast to hyaluronic acid crosslinked in preparation Haymovis® indicated full recovery of its elasticity after repeated mechanical impact that translates into a more pronounced ability to absorb shocks caused by mechanical loading, for a better protection of the joint.
Biotribologicheskie excellent properties. Biotribologicheskie properties are related to the ability of a substance to lubricate the surface of cartilage in mutual contact and, thus, protecting them from friction and mechanical impact that occurs during motion.
Hydrogels may have the same coefficients of viscosity, elasticity, but this does not mean that they have the same lubricating effect within the joint.
The drug Himovis shows the best lubricating properties among natural polymers and polymer cross-linked as in a simulation of healthy cartilage, and cartilage degradation. Physico-chemical and biological properties described for Haymovis preparation are the basis of clinical efficacy, which was found in this drug in the treatment of osteoarthritis, and makes it the drug of choice in the treatment of acute and traumatic chondropathy athletes, professionals and amateurs.
Restoring the viscosity of synovial fluid drug Haymovis® effectively reduces pain, restores and preserves joint function in patients with osteoarthritis of the shoulder joint biomechanical and biological characteristics of the drug Haymovis®sozdayut prerequisites for expanding the indications for its use in diseases caused by sports.
Phidias Farmatseutitsi SpA, Italy
The main component of the medical device Haymovisa 24 mg / 3 ml prefilled syringe – geksadetsilamid sodium hyaluronate (HYADD®4), obtained by amidation of the carboxyl group of sodium hyaluronate with hexadecylamine.
The list of raw materials: – HYADD®4 (geksadetsilamid sodium hyaluronate) – 24 mg;
– sodium chloride mg -25.5;
– sodium hydrogen phosphate dodecahydrate (Na2HP04 x 12H20) – 1,35 mg;
– sodium dihydrogen phosphate dihydrate (Na2HP04 x 2H20) – 0.33 mg;
– water for injection to 3 ml (q.s.).
For intraarticular administration in trauma and sports medicine
Not administered to patients with established hypersensitivity to individual components of the product or in case of skin diseases or infection at the injection site.
Local pain, swelling, heat and redness in rare cases may occur at the injection site, such symptoms are usually mild degree and going.
It reported more severe inflammatory reactions, with precipitation of crystals of sodium pyrophosphate at intraarticular injection of sodium hyaluronate, although the relationship is not revealed.
Failure to observe the general precautions and inadequate aseptic processing of the injection site, septic arthritis can occur in rare cases, as with any intra-articular treatment.
– Keep the medical device to be in their original containers at a temperature of from 2 to 25 ° C.
– Do not freeze.
Recommendations for use
Medical device “Haymovis” administered using a sterile needle (18 or 20 gauge) in the affected joint (see. Figure 1) once a week course of treatment does not exceed 3 weeks.
refresher courses can be carried out if necessary.
A single treatment usually consists of the introduction of the medical device “Haymovis” 1 large or 2 medium or 3-5 small joints.
Multiplicity is determined individually: estimated results of each of the previous procedure, established by the testimony of its recurrence.